Results 91 to 100 of about 175,837 (263)

A Review of Current and Pipeline Drugs for Treatment of Melanoma

Pharmaceuticals
Malignant melanoma is the most aggressive form of skin cancer. Standard treatment options include surgery, radiation therapy, systemic chemotherapy, targeted therapy, and immunotherapy. Combining these modalities often yields better responses. Surgery is
Nicole Natarelli, Sarah J. Aleman, Isabella M. Mark, Jasmine T. Tran, Sean Kwak, Elizabeth Botto, Shaliz Aflatooni, Michael J. Diaz, Shari R. Lipner   +8 more
doaj   +1 more source

Immunological effects of BRAF+MEK inhibition

OncoImmunology, 2018
Recent developments in immunotherapy have prolonged overall survival in metastatic melanoma with the possibility to reach a long-term benefit. Targeted therapies based on BRAF and MEK inhibition also seem to have a long-term beneficial effect, which is ...
Paolo A. Ascierto, Reinhard Dummer
doaj   +1 more source

Advances in systemic treatment of melanoma

Annals of Oncology, 2010
After decades of phase III trials failing to demonstrate an impact on survival of various drugs in metastatic melanoma there are finally significant advances in systemic therapies for melanoma emerging. Novel ways to modulate the immune system by monoclonal antibodies as well as various signalling pathway inhibitors are responsible for creating a whole
openaire   +2 more sources

Genome‐Wide CRISPR Screen Identifies a microRNA Orchestrating Pleiotropic Resistance to Targeted Therapy and T Cell Immunity in Melanoma

Advanced Science, EarlyView.
A genome‐wide microRNA CRISPR screen identifies miR‐18a as a master regulator of cross‐resistance in melanoma. Loss of miR‐18a activates the AJUBA–YAP/Hippo axis to confer BRAFi resistance and enhances THBS1–CD47 interaction to impair CD8+ T cell immunity. hnRNP A1 is identified as an upstream regulator of miR‐18a processing.
Zhao Wang, Haotian Liu, Xueqi Wang, Jianjin Teng, Zihan Zheng, Jingya Zhang, Wanyi Xiao, Qian Liang, Jiaxin Li, Xiaomeng Jia, Xin Feng, Hongzhang Cui, Menghan Luo, Tielong Yang, Liuxing Wu, Ke Zhao, Weilong Yang, Mulin Jun Li, Dandan Huang, Jilong Yang   +19 more
wiley   +1 more source

The serum metabolome serves as a diagnostic biomarker and discriminates patients with melanoma from healthy individuals

Cell Reports Medicine
Summary: Melanoma is a deadly cancer with increasing incidence and mortality rates, and biomarkers for diagnosis are urgently needed. The impact of the microbiome, genetic factors, and immunologic markers on disease outcomes is described, but a ...
Yasser Morsy, Barbara Hubeli, Patrick Turko, Marjam Barysch, Julia M. Martínez-Gómez, Nicola Zamboni, Gerhard Rogler, Reinhard Dummer, Mitchell P. Levesque, Michael Scharl   +9 more
doaj   +1 more source

Light‐Activatable Nitric Oxide Release via Intramolecular Electron Transfer for Tumor Pyroptosis Induction

Advanced Science, EarlyView.
This work proposes a novel strategy to fabricate unimolecular pyroptosis photoinitiators activated by deep‐red light at low light doses. It relies on a photosensitization mechanism to trigger nitric oxide (NO) release from benzisothiadiazole‐based N‐nitrosanilines without modification of nitro moieties, thereby boosting pyroptosis‐mediated ...
Chuangxin Zhang, Ruipeng Li, Yunxia Wang, Feng Liu, Liheng Feng   +4 more
wiley   +1 more source

The Development and Pilot Clinical Study of CD147 Targeted Antagonistic Peptide Probe for Tumor Imaging

Advanced Science, EarlyView.
This study establishes [68Ga]Ga‐DOTA‐AP9 as a first‐in‐human CD147‐targeted PET tracer with favorable safety and specific tumor uptake. Tracer accumulation correlates with CD147 expression in patients, enabling noninvasive quantification of CD147‐positive malignancies.
Xiaokun Ma, Rui Guo, Dongfeng Niu, Yufei Song, Zhenyao Zhang, Xiangxi Meng, Lili Mao, Haifeng Huang, Hua Zhu, Zhi Yang, Teli Liu   +10 more
wiley   +1 more source

Emerging options for the treatment of melanoma – focus on ipilimumab

ImmunoTargets and Therapy, 2014
Claire Roddie, Karl S Peggs UCL Cancer Institute, Department of Hematology, London, UK Abstract: Ipilimumab is a fully human immunoglobulin subclass G1 anticytotoxic-T-lymphocyte-antigen-4 monoclonal antibody.
Roddie C, Peggs KS
doaj  

Diffuse Melanosis Cutis Under Immuno‐ and Targeted Therapy

JEADV Clinical Practice
In patients with highly advanced melanoma, rarely a diffuse melanosis cutis (DMC) can be noticed. Even though the condition is generally harmless itself, it can have a significant impact on the patient's well‐being as an obvious mark of the disease.
Christiane Cussigh, Lara‐Elena Hakim‐Meibodi, Alexander H. Enk, Jessica C. Hassel   +3 more
doaj   +1 more source

Advanced stage melanoma during pregnancy: recommendations from a retrospective, multicentre, registry-based studyResearch in context

EClinicalMedicine
Summary: Background: Diagnosis and treatment of advanced melanoma during pregnancy represents a major challenge, with scarce data on outcome or management available. Therefore, the Melanoma Pregnancy Taskforce collected real-world data to understand the
Jessica S.W. Borgers, Douglas B. Johnson, Elisabeth Livingstone, Dirk Schadendorf, Elizabeth I. Buchbinder, Lauren E. Haydu, Laura Gohil, William A. Robinson, Inderjit Mehmi, Omid Hamid, Michelle Ferreira, April K.S. Salama, Florentia Dimitriou, Matteo S. Carlino, Georgina V. Long, Paolo A. Ascierto, Ester Simeone, Yana G. Najjar, Geke A.P. Hospers, Jacob Choi, Sunandana Chandra, Jeffrey D. Wayne, Carlos I.R. García, Wen Xu, Céleste Lebbé, Laetitia Da-Meda, Victoria Atkinson, Meredith Mckean, Andrea Forschner, Elliot A. Asare, Antonios Daletzakis, Jolyn S. Taylor, Frédéric Amant, Katy K. Tsai, Zeynep Eroglu, John B.A.G. Haanen, Isabella C. Glitza de Oliva   +36 more
doaj   +1 more source